[CAS NO. 1864871-20-4] Cusatuzumab
PRODUCTS SPECIFICATIONS [1864871-20-4]
DESCRIPTION [1864871-20-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | - |
| SMILES | [Cusatuzumab] |
1 Publications Citing Use of MCE
Summary
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis . Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) [1] .
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04264806 | Janssen Research & Development, LLC|argenx |
Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic
|
May 6, 2021 | Phase 2 |
| NCT04023526 | Janssen Research & Development, LLC|argenx |
Leukemia, Myeloid, Acute
|
July 29, 2019 | Phase 2 |
| NCT04241549 | Janssen Pharmaceutical K.K.|argenx |
Leukemia, Myeloid, Acute
|
March 25, 2020 | Phase 1 |
| NCT04150887 | Janssen Research & Development, LLC|argenx |
Leukemia, Myeloid, Acute
|
December 23, 2019 | Phase 1 |
Appearance
Liquid
Shipping
Shipping with dry ice.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.